You are here

Press Release Archive

 
- Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry(TM) (Maraviroc)

(BUSINESS WIRE)--Nearly three times as many patients receiving Selzentry, in addition to an optimized background regimen, achieved undetectable levels of HIV virus compared with those receiving an optimized regimen alone, according to 48 week data presented today in late-breaking sessions at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting. This newly approved CCR5 antagonist – the first new class of

 
- New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years

(BUSINESS WIRE)--Two new studies presented today at the European Association for the Study of Diabetes (EASD) meeting reinforce the efficacy and safety of Exubera (insulin human [rDNA origin]) Inhalation Powder for adults with diabetes. An eight-year extension study showed that Exubera was well-tolerated and effective at maintaining blood sugar control. A second eight-day, exploratory study with Exubera and Lantus®

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, Senior Vice President, Pfizer Inc., President, Worldwide Pharmaceutical Operations, at the 37th Annual Bank of America Investment Conference on Wednesday, September 19 at 9:00 a.m. Pacific Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on

 
- Pfizer to Share New Data and Portfolio Update on Infectious Disease Portfolio at ICAAC Meeting; Invites Public to View and Listen to Webcast of September 18 Analyst Meeting

(BUSINESS WIRE)--Pfizer Inc said today that the company plans to present key data on in-line medicines and pipeline research at the Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, Illinois. In addition, Pfizer plans to host an investor meeting on September 18th to review key updates on infectious disease medicines and pipeline research. The meeting will be webcast live from Chicago

 
- Canadian Court Finds Infringement of Lipitor Crystal Form Patent

(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s patent covering a crystalline form of atorvastatin, the active ingredient in Lipitor, would be infringed by Ranbaxy Laboratories Limited’s process for making their proposed generic atorvastatin product. The court granted the company’s application for an order preventing Ranbaxy from launching its product until

 
- Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer

(BUSINESS WIRE)--Pfizer announced today the initiation of a large, global Phase III clinical trial to evaluate the efficacy and safety of sunitinib malate, in combination with erlotinib, in previously treated patients with advanced non-small cell lung cancer (NSCLC). In addition, preliminary results from a Phase II study, presented this week at the International Association for the Study of Lung Cancer (IASLC) World Conference in Seoul,

 
- Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education - Mobilize Against Malaria

(BUSINESS WIRE)--To help address critical gaps in malaria treatment and education, Pfizer today announced the launch of Mobilize Against Malaria. This three-country initiative comprising Kenya, Ghana and Senegal will be implemented over the course of five years (2007-2011). Pfizer has selected key international and local health experts to develop and implement public health interventions that engage and educate treatment providers and patients

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer Jeffrey B. Kindler at the 20th Annual Bear Stearns Health Care Conference on Monday, September 10th at 1:30p.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “the 20th

 
- Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows

(BUSINESS WIRE)--An observational study of a large United Kingdom primary care database showed that switching patients from Pfizer’s Lipitor® (atorvastatin calcium) Tablets to simvastatin was associated with a 30 percent increase in the relative risk of major cardiovascular events, including heart attacks, strokes and certain types of heart surgeries, or death compared to patients who remained on Lipitor therapy

 
- Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Bristol-Myers Squibb Company (NYSE:BMY) (“companies”) today announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007. Pfizer’s DGAT-1 discovery program includes advanced pre-clinical compounds with potential applications for the

 
- Pfizer Names Frank A. D'Amelio Chief Financial Officer

(BUSINESS WIRE)--Pfizer today announced that Frank A. D’Amelio, a senior executive with almost three decades of extensive operating and financial experience at AT&T, Lucent Technologies and Alcatel-Lucent, including serving as both chief operating officer and chief financial officer at Lucent, will become Pfizer’s Senior Vice President and Chief Financial Officer effective in mid-September. Mr. D’Amelio, who is

 
- Pfizer's SelzentryTM (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA

(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved SelzentryTM (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV. “There is a profound need for new

 
- Breast Cancer Guidelines Confirm Central Role of 'Switch Strategy'; Recommendations of St Gallen Panel Support Exemestane Indication

(BUSINESS WIRE)--Guidelines from the 2007 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, published today in the Annals of Oncology (http://annonc.oxfordjournals.org), confirm the value of switching from tamoxifen to an aromatase inhibitor (AI), such as exemestane, for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.i Approximately 360,000 women in

 
- First Medication to Prevent and Treat Vomiting in Dogs Now Available by Prescription

(BUSINESS WIRE)--Pfizer Animal Health, a business of Pfizer Inc (NYSE: PFE), announced today that Cerenia™ (maropitant citrate), the first and only FDA-approved medication for the prevention and treatment of canine vomiting from a wide range of causes, including motion sickness, is now available by prescription in the United States. Vomiting is one of the most common reasons owners take their dogs to the veterinarian. According

 
- Spanish Court Rules in Pfizer's Favor, Upholds Lipitor Patent

(BUSINESS WIRE)--Pfizer Inc said today that a Spanish court has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor. The Commercial Court of First Instance Number 4 in Barcelona, which issued the ruling, found a second patent covering a stabilized formulation that includes atorvastatin is invalid. The patents were challenged by generic manufacturer Ranbaxy

 
- Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show

(BUSINESS WIRE)--Rates of virologic suppression in patients receiving Pfizer’s novel CCR5 antagonist, maraviroc, compared to efavirenz (EFV) were 70.6% vs. 73.1% for <400 copies/ml and 65.3% vs. 69.3% at <50 copies/ml in the full analysis set (FAS) study population (n= 360, maraviroc/ n= 361, efavirenz), according to a late breaker presentation at the International AIDS Society conference in Sydney, Australia. Increases in

 
- Pfizer Receives Positive Opinion from CHMP for Celsentri(R) (maraviroc) for Treatment-Experienced Patients Infected with CCR5-Tropic HIV-1

(BUSINESS WIRE)--Pfizer Inc announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending marketing authorization for Celsentri® (maraviroc), the first CCR5 antagonist for use in combination with other antiretroviral agents for treatment-experienced adult patients where only CCR5-tropic virus is detectable. The CHMP’s positive

 
- Pfizer Announces First Occupant in its Science Incubator

(BUSINESS WIRE)-- Pfizer today announced its first occupant for the company’s Incubator – a new development where scientific entrepreneurs progress their ideas towards innovative treatments for serious diseases. Vaughn Smider MD, PhD, an assistant professor at The Scripps Research Institute, in La Jolla CA, will work to develop a unique technology to identify antibodies that might lead to new therapies. He will

 
- Pfizer Reports Second-Quarter 2007 Results, Reconfirms Full-Year 2007 and 2008 Financial Guidance and Updates Progress on Immediate Business Priorities

(BUSINESS WIRE)--Pfizer: ($ millions, except per-share amounts)           Second Quarter   Year to Date     2007  

 
- High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011

(BUSINESS WIRE)--Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent (Irish Patent Number 60014) expires in November 2011. “

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.